ANTERIS TECHNOLOGIES GLOBAL Stock Price, News & Analysis

Anteris Technologies Global Corp (NASDAQ: AVR) announced the closing of a public offering of 40,000,000 common shares and a private placement of 15,652,173 shares to Medtronic, each at $5.75 per share. Gross proceeds from both transactions were approximately $320 million before fees and expenses. Underwriters included Barclays, Wells Fargo Securities and Cantor; Wells Fargo acted as placement agent for the Medtronic sale. The company said net proceeds will fund the global pivotal PARADIGM Trial for the DurAVR THV, expand manufacturing, support R&D for v2vmedtech, and for working capital and general corporate purposes.

Anteris Technologies Global Corp (NASDAQ: AVR) priced a public offering of 34,782,609 shares at $5.75 per share, generating approximately $200.0 million in gross proceeds, with expected closing on January 22, 2026.

The company granted underwriters a 30-day option to buy an additional 5,217,391 shares. Separately, Anteris agreed to a private placement to Medtronic of up to $90.0 million of shares at the same price, subject to a minimum purchase equal to 16.0% and a maximum of 19.99% of post-offering outstanding shares; the private placement is contingent on the Offering.

Net proceeds are intended to fund the global pivotal PARADIGM Trial for the DurAVR THV, expand manufacturing, support R&D at v2vmedtech, and for working capital.

Anteris Technologies Global Corp (NASDAQ: AVR) announced a proposed public offering of $200.0 million of common stock with a 30-day underwriter option for an additional $30.0 million. Concurrently, Anteris agreed to a private placement with Medtronic for up to $90.0 million of shares at the public offering price, subject to a minimum purchase equal to 16.0% and a maximum of 19.99% of outstanding shares after the Offering. Completion of Medtronic's Private Placement is contingent on completion of the Offering; the Offering is not contingent on the Private Placement.

Proceeds, together with existing cash, are intended to fund the PARADIGM pivotal trial for the DurAVR THV, manufacturing expansion, R&D for v2vmedtech, working capital, and general corporate purposes. Barclays, Wells Fargo Securities and Cantor are joint book-runners; Wells Fargo is placement agent for the private placement.

Anteris Technologies (NASDAQ: AVR) presented 30-day pooled outcomes for 100 small‑annulus severe aortic stenosis patients treated with the DurAVR® THV at PCR London Valves (Nov 17, 2025).

Key results: mean pressure gradient 8.2 ± 3.1 mmHg, effective orifice area 2.2 ± 0.3 cm2, 0 valve‑related deaths, 0 moderate/severe paravalvular leak, and 97% freedom from moderate/severe prosthesis‑patient mismatch; technical success was 100% in the last 50 consecutive implants. The analysis pools EMBARK and early feasibility studies and represents ~20% of planned PARADIGM randomized cohort enrollment.

Anteris (NASDAQ: AVR) reported Q3 2025 results and a corporate update focused on advancing the PARADIGM pivotal trial and scaling manufacturing. Key regulatory milestones included FDA approval to commence U.S. recruitment announced in November 2025 and Danish Medicines Agency approval with the first PARADIGM patients treated in Denmark in October 2025. The company progressed site readiness across the U.S., Europe and Canada, advanced QMS and ISO 13485 preparation, and continued manufacturing scale-up for DurAVR THV production.

Financial highlights: net operating cash outflows $59.3M for the nine months ended Sept 30, 2025; R&D $16.8M and SG&A $5.8M for Q3; cash and cash equivalents of $9.1M at Sept 30, 2025.

Anteris (NASDAQ:AVR) announced that the U.S. Food and Drug Administration granted approval to initiate the PARADIGM global Investigational Device Exemption (IDE) clinical trial for the DurAVR® Transcatheter Heart Valve (THV) on November 3, 2025. The randomized pivotal trial will compare the DurAVR biomimetic valve to commercial TAVR devices in patients with severe calcific aortic stenosis and is intended to support a future PMA submission.

The company said U.S. patient recruitment can now begin, and noted the trial recently launched with first patients treated in Denmark. The study is co-chaired by Dr. Michael J. Reardon and Professor Stephan Windecker.

Anteris (NASDAQ: AVR) reported one-year pooled outcomes for the DurAVR® Transcatheter Heart Valve (THV) in patients with small aortic annuli (mean annulus area 396 ± 37 mm2).

Key results: EOA 2.1 ± 0.2 cm2, mean pressure gradient 8.6 ± 2.6 mmHg, no valve-related mortality and no moderate or severe paravalvular leak at one year; 30-day prosthesis-patient mismatch was 1.5% versus 11.2%–35.3% for current devices. The pooled cohort included 65 small-annulus patients from EMBARK and a US early feasibility study; >100 patients have been implanted overall. Results will be evaluated further in the randomized PARADIGM pivotal trial (NCT07194265).

Anteris Technologies (NASDAQ: AVR) announced on October 27, 2025 that the first patients were enrolled and successfully treated in the global pivotal PARADIGM Trial evaluating the DurAVR® Transcatheter Heart Valve (THV) for severe calcific aortic stenosis.

The initial procedures were performed at Rigshospitalet, Copenhagen by Prof. Dr. Ole De Backer. The head-to-head study will randomize patients across surgical risk groups and builds on an existing clinical dataset of 130 patients previously treated with DurAVR® (including de novo, valve-in-valve, and bicuspid anatomies). Anteris plans near-term expansion of PARADIGM into the United States, Europe and Canada to accelerate enrollment and evidence generation toward commercialization.

Anteris Technologies (NASDAQ: AVR) announced that one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) will be presented at TCT 2025 on October 27, 2025 at 2:27pm GMT-7 in the Innovation Theater, Moscone Center, San Francisco.

The oral presentation, titled “The DurAVR® Biomimetic TAVR System in Patients with Small Aortic Annuli (Anteris): One-Year Clinical and Hemodynamic Outcomes,” summarizes outcomes in over 100 patients with symptomatic severe aortic stenosis and small aortic annuli (annulus area 396 ± 37 mm2). The company said the outcomes to date are encouraging and will be further evaluated in the global pivotal PARADIGM Trial, a prospective randomized controlled trial comparing DurAVR THV to commercially available TAVRs for safety and effectiveness.